Design Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Design Therapeutics, Inc. (DSGN) reported Revenue from Contract with Customer, Excluding Assessed Tax of $226.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2022-03-10
- Design Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-12-31 was $33.00K.
- Design Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $20.00K.
- Design Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $31.00K.
- Design Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-03-31 was $142.00K.
- Design Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $226.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $53.00K derived: sum of 2 quarters · filed 2022-03-10 | $84.00K derived: sum of 3 quarters · filed 2022-03-10 | $226.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $20.00K 10-Q · filed 2021-11-09 | $51.00K derived: sum of 2 quarters · filed 2021-11-09 | $193.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $31.00K 10-Q · filed 2021-08-09 | $173.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $142.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |